Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03865667
Other study ID # 12-LJH-002G
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 15, 2019
Est. completion date January 1, 2032

Study information

Verified date April 2023
Source MicroPort Orthopedics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 63
Est. completion date January 1, 2032
Est. primary completion date January 1, 2032
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Newly or previously implanted subjects must meet all the following inclusion Criteria: - Has undergone primary Total Hip Arthroscopy for any of the following: - Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;lnflammatory degenerative joint disease such as rheumatoid arthritis; or - Correction of functional deformity; - Subject is implanted with the PROFEMUR® Preserve Femoral Stem(s) and cobalt-chromium Modular Neck; - Subject is willing and able to complete required study visits or assessments through the 10 year postoperative follow-up schedule; - Subject is implanted with WMT or MPO head, cup and liner. Newly or previously implanted bilateral subjects can have both Total Hip Arthroscopy enrolled in the study provided: 1) the specified PROFEMUR® Preserve Femoral Stems and cobalt-chromium Modular Necks were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second Total Hip Arthroscopy. Previously implanted subjects who had undergone revision of any Total Hip Arthroscopy component including the PROFEMUR® Preserve Femoral Stem(s) or, cobalt-chromium Modular Neck will also be eligible to be considered for this study. Exclusion Criteria: Subjects will be excluded if they meet any of the following criteria: - Subjects implanted with non-MicroPort or Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners); - Subjects implanted with a PROFEMUR® Preserve stem assembled to a Titanium Modular Neck; - Subjects skeletally immature (less than 21 years of age) at time of primary Total Hip Arthroscopy surgery; - Subjects have or had an overt infection at the time of implantation; - Subjects have or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation; - Subjects have or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at time of implantation; - Subjects have or had inadequate neuromuscular status (e.g., prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable; - Subject has neuropathic joints; - Subject has hepatitis or HIV infection; - Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing; - Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol; - Subjects unwilling or unable to sign the Informed Consent document; - Subjects with documented substance abuse issues; - Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study; - Subjects who are incarcerated or have pending incarceration.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PROFEMUR® Preserve Femoral Stem
Total Hip Total Hip Arthroscopy

Locations

Country Name City State
Spain Dr. Manel Ribas Barcelona

Sponsors (1)

Lead Sponsor Collaborator
MicroPort Orthopedics Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is to evaluate component survivorship of the PROFEMUR® Preserve Femoral Stem and CoCr Modular Neck out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year. 10 years
Secondary To determine the cumulative incidence of component revision of the PROFEMUR® Preserve Femoral Stem and CoCr Modular Neck at specified intervals out to 10 years follow-up. Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation. Time Frame: 2-5 years, 5-7 years, and 10 years
Secondary To characterize functional scores, as assessed by Oxford Hip and EQ-5D-3L scores. The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'. EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems. Time Frame: 2-5 years, 5-7 years, and 10 years
Secondary To evaluate the presence and the zones of radiolucencies surrounding the implanted femoral components. Radiolucencies are described around 7 zones and we will be reporting the number of hips with radiolucencies present at a given zone. 2-5 years, 5-7 years, and 10 years
Secondary To characterize of adverse events and adverse device effects. Adverse Events will be summarized as the total number of Adverse Events (AE), Adverse Device Effect (ADE) by grade, severity, and relationship to the device and surgery. Number of patients experiencing such AEs and ADEs will be also provided. 2-5 years, 5-7 years, and 10 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02314702 - Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems
Completed NCT03272139 - Interscalene Block Versus Superior Trunk Block Phase 4
Completed NCT03271151 - Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty Phase 4
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT01256216 - Signature Versus Computer Assisted Surgery Study N/A
Completed NCT03337243 - Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis N/A
Active, not recruiting NCT03294408 - Multimodal Imaging of Subchondral Bone in Knee Osteoarthritis : Predictive Model N/A
Withdrawn NCT02668211 - Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components N/A
Active, not recruiting NCT02239783 - Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems
Terminated NCT00698347 - A Clinical Investigation of the M2a-Magnum™ Hip System N/A
Completed NCT00223353 - Quantitative Gait Analysis for Clinical Decision Making N/A
Recruiting NCT04037735 - RSA-RCT: Attune S+ TKA Versus Sigma TKA N/A
Terminated NCT03575975 - 3D X-ray Motion Analysis of Ankle-foot Motion After Total Ankle Arthroplasty
Completed NCT03894514 - Multi-variable Prediction Model of Total Knee Replacement Outcome
Completed NCT02865447 - Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis
Enrolling by invitation NCT03576573 - Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Completed NCT02390336 - Mobilization With Movement in Patients With Osteoarthritis of the Hip N/A
Terminated NCT03293719 - Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic
Active, not recruiting NCT02823834 - PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components